|Dr. Todd C. Brady M.D., Ph.D.||CEO, Pres & Director||769.55k||N/A||1972|
|Mr. Joshua Reed M.B.A.||Chief Financial Officer||583.49k||N/A||1973|
|Dr. David J. Clark||Consultant||584.2k||N/A||1965|
|Dr. Stephen G. Machatha||Sr. VP of Technical Operations||N/A||N/A||1977|
|Ms. Mary Taylor M.P.H.||Sr. VP of Regulatory Affairs||N/A||N/A||1959|
|Mr. David B. McMullin M.B.A.||Chief Bus. Officer||N/A||N/A||1975|
|Dr. James A. Gow M.D.||Sr. VP of Clinical Devel.||N/A||N/A||1967|
|Mr. Bruce Greenberg CPA, M.B.A.||VP & Controller||N/A||N/A||N/A|
|Adam Brockman||Director of Toxicology & Pharmacology||N/A||N/A||N/A|
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, a sight-threatening retinal disease. The company's portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.
Aldeyra Therapeutics, Inc.’s ISS Governance QualityScore as of November 1, 2019 is 9. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 10.